Sensydia

company

About

Developer of a portable, point-of-care hemodynamic measurement system that uses proprietary sensor tech and machine learning to guide care.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$3.72M
Industries
Artificial Intelligence,Health Care,Medical Device,Wearables,Wireless
Founded date
Jan 1, 2015
Number Of Employee
1 - 10
Operating Status
Active

Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$5.68M
Sensydia has raised a total of $5.68M in funding over 2 rounds. Their latest funding was raised on Aug 2, 2017 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 2, 2017 Series B $3.72M 1 Colle Capital Partners Detail
Mar 1, 2016 Series A $1.95M 1 Colle Capital Partners Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Sensydia is funded by 1 investors. Colle Capital Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Colle Capital Partners Yes Series B